ZIOPHARM Oncology (NASDAQ:ZIOP)

CAPS Rating: 2 out of 5

Results 1 - 10 of 10

Recs

0
Member Avatar pchop12316 (72.29) Submitted: 12/15/2014 2:47:26 PM : Underperform Start Price: $4.02 ZIOP Score: -16.10

likely to keep going down in price

Recs

1
Member Avatar zzlangerhans (99.85) Submitted: 11/14/2014 4:04:41 PM : Underperform Start Price: $3.70 ZIOP Score: -28.48

Ziopharm is up a decent chunk today, icing on the cake for anyone who found the stub tasty at October lows under 2.5. Nevertheless, I don't see this upswing carrying on past the company's presentations at AACR at the beginning of December. It seems all Ziopharm had to do was make noise about CAR-T to tack on 40M in market cap, but it will soon become apparent that their efforts are very preliminary and they are far behind Kite, Juno, and Novartis among others. I expect the updates on Ad-RTS-IL-12 to be immaterial as well. Meanwhile, the company seems to be brushing MATISSE under the rug, as a promised interim OS analysis has failed to materialize. Ziopharm mutters something about the OS data being presented at a meeting in 2015 in their latest 10Q. Darinaparsin? The phase I trial of the oral formulation is fully enrolled, same as it was six months ago. Don't ask about indibulin. The company doesn't mention it even though it is still supposedly in development for breast cancer.

I know no one cares anymore about Ziopharm's small molecule platform. But the fact that they still find it necessary to obfuscate the failures rather than simply concede defeat in that area and move forward is an indication that management simply cannot be trusted. The company is promotional and cash is running low, which tells me that anyone buying into a run-up in the stock is going to get burned.

Recs

0
Member Avatar 3kidsjones (96.34) Submitted: 10/27/2014 8:33:30 PM : Outperform Start Price: $3.45 ZIOP Score: +34.20

Randal "Captain" Kirk going to help take this stock to another galaxy. Innovative approach to cancer in an industry in dire need of innovation. Deals coming soon for this company that will help drive much higher valuation.

Recs

0
Member Avatar joaquingrech (97.80) Submitted: 8/14/2014 4:17:04 PM : Outperform Start Price: $3.15 ZIOP Score: +48.74

this one is a lottery really. No way to know whether they will be profitable because they are on early stage tests, but if they do.. they will be a money making machine

Recs

0
Member Avatar Aurum (56.89) Submitted: 7/29/2014 12:47:10 PM : Outperform Start Price: $3.26 ZIOP Score: +43.16

Part of a broader pick of micro cap biotechs with encouraging preliminary clinical trial data and significant upside.

Recs

0
Member Avatar MystereX (69.44) Submitted: 11/1/2013 1:39:54 PM : Outperform Start Price: $3.55 ZIOP Score: +17.76

Ad-RST-IL-12 UPDATE

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 9/26/2013 5:35:43 AM : Outperform Start Price: $3.20 ZIOP Score: +28.03

monthly IHS

Recs

0
Member Avatar Ezquire65 (34.56) Submitted: 5/22/2012 2:57:23 PM : Outperform Start Price: $4.74 ZIOP Score: -42.64

A true speculative play with huge upside potential. With master investory RJ Kirk behind this security and from all accounts many promising developments. This could be the proverbial 5 bagger holy grail that FOOLS rarely see.

Recs

1
Member Avatar mavrant (< 20) Submitted: 6/2/2011 12:36:29 PM : Outperform Start Price: $6.74 ZIOP Score: -86.09

possible new technology

Recs

1
Member Avatar AGCAPS1 (37.79) Submitted: 1/26/2011 10:19:00 AM : Underperform Start Price: $5.98 ZIOP Score: +78.83

First review the released statements since 2009. Then read about what this company does. They research on eliminations of the existent cancer drugs side effects. This company works in drugs researching provided by Intrexon. If they become successful “many years away”, most likely the Intrexon will be the one profit from it. The stock is overpriced.

Results 1 - 10 of 10

Featured Broker Partners


Advertisement